This is the Anti-Doping Policy (ADP) for the Australian Women’s Natural Body Sculpting (AWNBS) Association. We have adopted and implemented this ADP in accordance with anti-doping principles as set out in the National Anti-Doping scheme administered by the Australian Sports Anti-Doping Authority (ASADA).
Any definition and/or term of any AWNBS document can be interpreted as one and the same for the ADP.
This ADP applies to all Entrants in AWNBS Competitions. This includes but is not limited to:
(a) Entrants and/or Members of the AWNBS; or
(b) Personnel In training for or who compete from time to time in any competition or event in our sport.
2. All Competition or Member Support Personnel;
3. Event organisers; and
4. Other’s having access to our facilities and services for sporting purposes.
To be eligible to participate in any AWNBS Competition, the person agrees to be bound by and to comply with this ADP. By so participating or assisting, a person shall be deemed to have agreed to be bound by and comply with this ADP, whether a registered Member or not.
We may modify, update or generally amend this ADP from time to time as we see fit.
The objectives of this ADP are to:
1. Implement a anti-doping policy that works to prevent cheating by doping in AWNBS Competitions and by AWNBS Members; and
2. Promote and protect the image and reputation of the AWNBS.
5. PROHIBITED LIST / NON-APPROVED SUBSTANCES:
Any substance listed below is strictly prohibited at all times by the AWNBS. The AWNBS reserves the right to terminate the Membership of any Member of the AWNBS who tests positive for a non-approved substance or from any AWNBS Competition.
A Member may also be removed from the Competition if they refuse to undertake any AWNBS sanctioned drug test on the day of the Competition.
AWNBS PROHIBITED LIST (the LIST) 1. Anabolic Androgenic Steroids (AAS)
(a) Exogenous* AAS, including:
(i) 1-androstenediol (5α-androst-1-ene-3β,17β-diol)
(ii) 1-androstenedione (5α-androst-1-ene-3,17-dione)
(iii) 4-hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one)
(iv) methyl-1-testosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one)
(vii) 1-testosterone (17β-hydroxy-5α-androst-1-en-3-one)
(viii) T etrahydrogestrinone (17-hydroxy-18a-homo-19-nor-17α-pregna-4,9,11- trien-3-one)
(b) Endogenous** AAS when administered exogenously:
(i) androstenediol (androst-5-ene-3β,17β-diol)
(ii) androstenedione (androst-4-ene-3,17-dione)
(iii) dihydrotestosterone (17β-hydroxy-5α-androstan-3-one)
(iv) prasterone (dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17- one)
(vi) and their metabolites and isomers, including but not limited to:
(xviii) 4-androstenediol (androst-4-ene-3β,17β-diol)
(xix) 5-androstenedione (androst-5-ene-3,17-dione)
(xx) androsterone (3β-hydroxy-5α-androstan-17-one)
2. Other Anabolic Agents, including but not limited to:
(b) selective androgen receptor modulators (SARMs, e.g. andarine and ostarine)
5.1 PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES AND MIMETICS
1. Erythropoietin-Receptor agonists: (a) erythropoietins (EPO)
2. Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) and their releasing factors in males:
3. Growth Hormone (GH) and its releasing factors including:
(a) Growth Hormone Releasing Hormone (GHRH) and its analogues e.g.
(e) Growth Hormone Secretagogues (GHS) e.g
(f) ghrelin and ghrelin mimetics e.g.
(i) GH-Releasing Peptides (GHRPs) e.g.
(m) pralmorelin (GHRP-2).
4. Additional prohibited growth factor:
(a) Fibroblast Growth Factors (FGFs); Hepatocyte Growth Factor (HGF); Insulin-like Growth Factor-1 (IGF-1) and its analogues; Mechano Growth Factors (MGFs); Platelet-Derived Growth Factor (PDGF); Vascular-Endothelial Growth Factor (VEGF) and any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching.
5.2 BETA-2 AGONISTS
(a) Inhaled salbutamol (maximum 1600 micrograms over 24 hours);
(b) Inhaled formoterol (maximum delivered dose 54 micrograms over 24 hours); and
(c) Inhaled salmeterol in accordance with the manufacturers’ recommended therapeutic regimen.
5.3 HORMONE AND METABOLIC MODULATORS
The following hormone and metabolic modulators are prohibited:
All beta-2 agonists, including all optical isomers, e.g. d- and l- where relevant, are prohibited.
The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of the therapeutic inhaled dose up to the maximum indicated above.
1. Aromatase inhibitors including, but not limited to:
(c) androsta-1,4,6-triene-3,17-dione (androstatrienedione)
(d) 4-androstene-3,6,17 trione (6-oxo)
2. Selective estrogen receptor modulators (SERMs) including, but not limited to:
3. Other anti-estrogenic substances including, but not limited to:
4. Agents modifying myostatin function(s) including, but not limited, to:
(a) myostatin inhibitors.
5.4 DIURETICS AND MASKING AGENTS
The following diuretics and masking agents are prohibited, as are other substances with a similar chemical structure or similar biological effect(s).
Including, but not limited to:
(c) plasma expanders e.g. glycerol and intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol
(i) etacrynic acid
(n) thiazides, e.g. bendroflumethiazide
(o) chlorothiazide and hydrochlorothiazide
(q) vaptans, e.g. tolvaptan.
All stimulants, including all optical isomers e.g. d- and l- where relevant, are prohibited.
1. Stimulants include:
(d) metamfetamine (d-)
2. Specified Stimulants:
(b) epinephrine**** (adrenaline)
(e) methylhexaneamine (dimethylpentylamine) (DMA A Jacked)
(g) phenethylamine and its derivatives;
(c) diamorphine (heroin)
(d) fentanyl and its derivatives
(a) natural e.g. cannabis, hashish and marijuana
(b) synthetic delta 9-tetrahydrocannabinol (THC)
(c) cannabimimetics e.g. “Spice”, JWH-018, JWH-073, HU-210.
All glucocorticoids are prohibited when administered by oral, intravenous, intramuscular or rectal routes.
Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradol and synephrine are not considered Prohibited Substances.
6. PRESENCE OF A NON-APPROVED SUBSTANCE IN AN ATHLETE’S BODILY SPECIMEN
It is a Competitor’s or Member’s personal responsibility to ensure that no Prohibited Substance enters her body. Accordingly, it is not necessary for the AWNBS to establish that intent, fault, negligence or knowledge of the Competitor or Member be requisite in order to breach the ADP.
7. USE OR ATTEMPTED USE OF A NON-APPROVED SUBSTANCE
The AWNBS regards any or attempted application, ingestion, injection or consumption by any means of any Prohibited Substance or Prohibited Method. The success or otherwise of the Use of a Prohibited Substance or Prohibited Method is irrelevant. It is sufficient that the Prohibited Substance or Prohibited Method was Used or Attempted to be Used for a breach of the ADP to have occurred.
8. POSSESSION OF NON-APPROVED SUBSTANCES AND METHODS
Possession by a Competitor or Member at any time or place of a Prohibited Substance is a clear breach of the ADP and will result in termination of any relevant agreement with the AWNBS.
9. TRAFFICKING ANY NON-APPROVED SUSBTANCE
The administration or attempted administration of a Prohibited Substance or Prohibited Method to any Competitor or Member or the assisting, encouraging, aiding, abetting or any other activity that involves complicity and breaches the ADP will result in termination of any relevant agreement with the AWNBS.
10. BURDENS AND STANDARDS OF PROOF OF DOPING
AWNBS shall be solely responsible for determining whether a breach of the ADP has occurred. The standards approved shall be whether the AWNBS is satisfied on the balance of probabilities that a breach of the ADP has eventuated.
The finding of a breach of the ADP will result in the AWNBS imposing whatever form of sanction that is deemed fit on the Competitor or Member.
All Competitors or Members agree and covenant to comply with any sanction imposed by the AWNBS for a breach of the ADP.